Clinical Report: Subepithelial Myofibroblasts in Inflammatory Bowel Disease
Overview
Intestinal subepithelial myofibroblasts (ISEMFs) play a role in the pathogenesis of intestinal fibrosis associated with inflammatory bowel disease (IBD). This review discusses their physiological functions and pathological activation mechanisms.
Background
Inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis often lead to intestinal fibrosis, a complication that can result in bowel strictures and surgical interventions. Understanding the role of ISEMFs in fibrosis is essential.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
ISEMFs are central regulators of epithelial homeostasis and mucosal repair in the intestine.
Pathological activation of ISEMFs during chronic inflammation leads to excessive extracellular matrix deposition and fibrosis.
Profibrotic cytokines such as TGF-β1 and connective tissue growth factor are key mediators of ISEMF activation.
Recent advances in single-cell and spatial transcriptomics have revealed fibroblast heterogeneity and pathogenic subsets associated with fibrosis.
Clinical Implications
Understanding the mechanisms of ISEMF activation can inform the development of therapies aimed at mitigating fibrosis.
Conclusion
ISEMFs are pivotal in the development of intestinal fibrosis in IBD.
